XNAS
KALA
Market cap6mUSD
Oct 08, Last price
0.30USD
1D
-17.61%
1Q
-74.76%
IPO
-100.00%
Name
Kala Pharmaceuticals Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
-31.07%
Rev. gr., 5y
175.60%
Revenues
0
Net income
-27m
L-29.94%
CFO
-32m
L+8.88%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Key people
Chief Operating Officer · since 2017
Hongming Chen
Chief Scientific Officer · since 2014
Mary Reumuth
Chief Financial Officer, Treasurer · since 2017
Kim Brazzell
Chief Medical Officer · since 2013
Chairman of the Board, President, Chief Executive Officer · since 2017
Gregory Grunberg
Independent Director · since 2016
Lead Independent Director · since 2018
Robert Bradley Paull
Independent Director · since 2009
Independent Director · since 2015
Independent Director · since 2015
Legal address
c/o DELAWARE CORPORATE SERVICES INC., 901 N MARKET ST STE 705
WILMINGTON, DE 19901
US
WILMINGTON, DE 19901
US
Headquarters
490 Arsenal Way, Suite 120
Watertown, MA 02453
US
Watertown, MA 02453
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||